SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Speaker
Kalyan Ram Bhamidimarri, MD, MPH
Associate Professor
Chief, Division of Hepatology
University of Miami
Miami, FL

Moderator
Gregg Sherman, MD
Family Practice
Plantation, FL

Title
: The Epidemic of NASH: Current and Emerging Management and Treatment Strategies
Activity/Course #:
: NCME376
Cost:
: Free
Release/Start Date:
: May 15 2019
Expiration Date:
: May 14 2020
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Physicians, Nurse Practitioners, Physician Assistants
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.25 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease. NAFLD includes nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and is associated with liver cancer. NAFLD is associated with diabetes, obesity, and hyperlipidemia, and is considered to be the hepatic manifestation of metabolic syndrome. NAFLD patients with advanced fibrosis are at increased risk for all-cause mortality as well as cardiovascular and cancer related mortality.

The prevalence of NAFLD has been increasing with the increasing prevalence of obesity, diabetes, and metabolic syndrome. This activity will examine the clinical characteristics of those at high risk for NAFLD, how to distinguish non-alcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH), and the available and emerging treatment options for patients with NASH.

This webcast was recorded live at Conversations in Primary Care 2019 and is being used with the permission of the presenters.

 
Learning Objectives
After completing this program participants should be able to:
  1. Identify patients at high risk for nonalcoholic fatty liver disease (NAFLD)
  2. Distinguish non-alcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH) and understand how to stage the disease
  3. Implement ongoing evidence based general management of patients with NASH
  4. Describe the available and emerging treatment options for patients with NASH

 

How to obtain the CME Certificate
  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.25 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speaker
Kalyan Ram Bhamidimarri, MD, MPH serves on the scientific advisory board for Gilead, AbbVie, Merck, and Intercept Pharmaceuticals, Inc. Dr. Bhamidimarri is a disease state education speaker for Alexion. He has also received research grant support from Gilead, Conatus, Allergan/Tobira, and Genfit.

Activity Planning Committe
Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Intercept Pharmaceuticals, Inc.